eagle-i University of Hawaii at ManoaUniversity of Hawaii at Manoa
See it in Search
This page is a preview of the following resource. Continue onto eagle-i search using the button on the right to see the full record.

The BeST trial: a randomized phase II study of VEGF, RAF Kinase, and mTOR combination targeted therapy (CTT) with bevacizumab, sorafenib and temsirolimus in advanced renal cell carcinoma [BeST]

eagle-i ID


Resource Type

  1. Clinical trial


  1. ClinicalTrials.gov url
  2. Intervention
    Sorafenib tosylate
  3. Intervention
  4. Resource Description
    Overview : Bevacizumab and sorafenib may stop the growth of tumor cells by blocking blood flow to the tumor. Temsirolimus and sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving different combinations of bevacizumab, sorafenib, and temsirolimus may be more effective than bevacizumab alone in treating metastatic kidney cancer. Purpose: This randomized phase II trial is studying different combinations of bevacizumab, temsirolimus, and sorafenib to see how well they work compared with bevacizumab alone in treating patients with metastatic kidney cancer.antineoplastic combined chemotherapy protocols.
  5. Contact
    Berenberg, Jeffrey
  6. PI
    Berenberg, Jeffrey
  7. Topic
    prostate cancer
  8. Topic
    kidney cancer
  9. Study Population
    Eligible subjects must be at least 18 years old with no primary brain tumor, brain metastases, or other CNS disease. There must have been more than 4 weeks since biological therapy, surgery, or open biopsy was performed and more than 2 weeks since radiation therapy.
  10. Funded by
    Cancer Trials Support Unit
  11. Phase
    Phase 2 clinical trial
  12. Performed by
    Clinical Protocol & Data Management Shared Resource
Provenance Metadata About This Resource Record
Copyright © 2016 by the President and Fellows of Harvard College
The eagle-i Consortium is supported by NIH Grant #5U24RR029825-02 / Copyright 2016